Research Database

18 studies found

Positive

94.4%

Negative

0.0%

Inconclusive

5.6%

Page 1 of 1

InconclusiveReview/Other

Cannabinoid treatment for the symptoms of autism spectrum disorder

2024

AutismFragile X Syndrome

PositiveAnimal Study -

Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome

2023

Fragile X Syndrome

PositiveReview/Other

Cannabidiol as a personalized treatment for anxiety: clinical cases in Mexico

2022

Anxiety

PositiveClinical Trial

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)

2022

Fragile X Syndrome

PositiveReview/Other

Cannabidiol and Neurodevelopmental Disorders in Children

2021

ADD and ADHD

PositiveReview/Other

Potential therapeutic uses of cannabinoids to treat behavioural problems in children and adolescents with developmental disorders

2021

ADD and ADHD

PositiveAnimal Study -

Cannabidiol (CBD) Reduces Anxiety-Related Behavior in Mice via an FMRP-independent Mechanism

2019

Fragile X Syndrome

PositiveMeta-analysis -

A systematic review of cannabidiol dosing in clinical populations

2019

Addiction - Cannabis

PositiveReview/Other

A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome

2019

Fragile X Syndrome

PositiveReview/Other

Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature

2019

Fragile X Syndrome

PositiveReview/Other

Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer's disease and Less Well-Known Diseases.

2018

Alzheimer's Disease

PositiveAnimal Study -

Possible Therapeutic Doses of Cannabinoid Type 1 Receptor Antagonist Reverses Key Alterations in Fragile X Syndrome Mouse Model

2016

Behavioral Disorders

PositiveReview/Other

Enhancement of Anandamide-Mediated Endocannabinoid Signaling Corrects Autism-Related Social Impairment

2016

Autism

PositiveAnimal Study -

Endocannabinoid-mediated Improvement on a Test of Aversive Memory in a Mouse Model of Fragile X Syndrome

2015

Fragile X Syndrome

PositiveAnimal Study -

Homer Protein-Metabotropic Glutamate Receptor Binding Regulates Endocannabinoid Signaling and Affects Hyperexcitability in a Mouse Model of Fragile X Syndrome

2015

Fragile X Syndrome

PositiveReview/Other

Targeting the Endocannabinoid System in the Treatment of Fragile X Syndrome

2013

Autism

PositiveAnimal Study -

Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome.

2012

Behavioral Disorders

PositiveReview/Other

Enhanced Endocannabinoid Signaling Elevates Neuronal Excitability in Fragile X Syndrome

2010

Behavioral Disorders

Command Palette

Research Database

Cannabinoid treatment for the symptoms of autism spectrum disorder

Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome

Cannabidiol as a personalized treatment for anxiety: clinical cases in Mexico

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)

Cannabidiol and Neurodevelopmental Disorders in Children

Potential therapeutic uses of cannabinoids to treat behavioural problems in children and adolescents with developmental disorders

Cannabidiol (CBD) Reduces Anxiety-Related Behavior in Mice via an FMRP-independent Mechanism

A systematic review of cannabidiol dosing in clinical populations

A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome

Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature

Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer's disease and Less Well-Known Diseases.

Possible Therapeutic Doses of Cannabinoid Type 1 Receptor Antagonist Reverses Key Alterations in Fragile X Syndrome Mouse Model

Enhancement of Anandamide-Mediated Endocannabinoid Signaling Corrects Autism-Related Social Impairment

Endocannabinoid-mediated Improvement on a Test of Aversive Memory in a Mouse Model of Fragile X Syndrome

Homer Protein-Metabotropic Glutamate Receptor Binding Regulates Endocannabinoid Signaling and Affects Hyperexcitability in a Mouse Model of Fragile X Syndrome

Targeting the Endocannabinoid System in the Treatment of Fragile X Syndrome

Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome.

Enhanced Endocannabinoid Signaling Elevates Neuronal Excitability in Fragile X Syndrome